Keywords: Drug approval rates, USA, Europe, Oncology versus non-cancer drugs, Tufts CSDD

Oncology drugs get faster approvals than non-cancer drugs in USA, but opposite case in Europe, Tufts research finds

Article | 05 September 2012

Approval times for new oncology drugs in the USA during the last decade were shorter than those for non-oncology products, ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in